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Abstract  
 
Aims: Glycaemic variability – the visit-to-visit variation in HbA1c – plays a possible role 
in the development of micro and macrovascular disease in patients with diabetes. 
Whether HbA1c variability is a factor determining wound healing in diabetic foot ulcers 
remains unknown. We aimed to determine whether HbA1c variability is associated with 
foot ulcer healing time. 
 
Methods: A retrospective analysis of patients presenting to our specialist 
multidisciplinary foot clinic between July 2013 and March 2015, with at least three 
HbA1c measurements within five years of presentation and more than two follow-up 
reviews. HbA1c variation was measured by magnitude of standard deviation. 
 
Results: 629 new referrals were seen between July 2013 and March 2015. Of these, 
172 patients had their number of days to healing recorded and sufficient numbers of 
HbA1c values to determine variability. The overall geometric mean days to heal was 
91.1 days (SD 80.8 to 102.7). In the low HbA1c variability group the geometric mean 
days to heal was 78.0 days (60.2 to 101.2) vs 126.9 days (102.0 to 158.0) in the high 
Hb1Ac variability group (p=0.032). Those with low HbA1c (< 58 mmol/mol) and low 
variability healed faster than those with high HbA1c and high variability (73.5 days [59.5 
to 90.8] vs 111.0 days [92.0 to 134.0], p=0.007). Additionally, our results show that time 
to healing is more dependent on the mean HbA1c than the variability in HbA1c 
(p=0.007). 
  
 
Conclusions/interpretation: Our data suggest that there was a significant association 
between HbA1c variability and healing time in diabetic foot ulcers.  
 
Key words: Glycaemic variability; HbA1c variability; ulcers; wound healing  
  
Introduction 
Foot ulcers are a common complication of diabetes and recent data has shown that 
across the UK, foot disease is the most common reason for a ‘diabetes specific’ acute 
hospital admission [1]. Previous work has suggested that up to 33% of ulcers fail to heal 
within 1 year [2,3], with a further 28% requiring lower extremity amputation within 2 
years of initial presentation [4]. The 5-year mortality rate of people with diabetes related 
foot ulcers has been shown to be between 69-79%, with mortality increasing 
significantly if other comorbidities are present [5,6].  
 
It is well recognised that chronic hyperglycaemia, as measured by HbA1c, is the key 
risk factor for the development of diabetes-related micro and macrovascular 
complications [7,8]. Several recent studies have suggested that there are relationships 
between the development of micro and macrovascular complications and the variation 
between HbA1c values at successive clinic visits [9,10,11,12,13,14]. These changes 
have been termed glycaemic variability. Besides visit-to-visit variation in HbA1c, other 
definitions of glycaemic variability include fluctuations in glucose concentrations or 
variability between daily glucose means [15].  
 
To our knowledge, there are currently no data assessing the impact of glycaemic 
variability on the time taken to achieve wound healing in people with diabetes related 
foot ulcers. That was the aim of the present study.  
 
Methods 
  
We conducted a retrospective case note analysis of patients attending our specialist 
multidisciplinary foot clinic in Norwich (Norfolk, UK), between July 2013 and March 
2015. Patients were included if they had at least three HbA1c values taken within the 
five years prior to their first presentation to our foot clinic with a diabetes related foot 
ulcer. In addition, they were only included if they had attended more than 2 follow-up 
reviews within the first year of their initial presentation with a foot ulcer. Patients were 
excluded if they had any of the following: Charcot neuroarthropathy, venous ulceration, 
dermatological conditions unrelated to their diabetes, or referral for other reasons 
(including, but not limited to, callus, nail care, or for provision of hospital footwear). 
Individuals were included in the analysis if they had sequential ulcers.  
 
Baseline demographics and subsequent data were collected from the centralised 
hospital electronic clinic records, multidisciplinary clinic letters, and an electronic 
pathology database. Type, duration and management of diabetes were recorded. Data 
on HbA1c and renal function (estimated glomerular filtrate rate) prior to initial 
presentation to the foot clinic were collected. Previous history of foot diseases (ulcers 
and/or amputations), extent of peripheral arterial disease and history of 
revascularisation were also recorded. Data on the number of foot ulcers and their grade 
according to the University of Texas Wound Classification [4,16] were gathered. 
Patients were followed up for at least 1 year after their initial presentation. Ulcer healing 
was defined as complete wound closure with wound epithelisation and no recurrence at 
6 weeks follow up. 
  
  
This was a retrospective case notes analysis study and as such the Norfolk and 
Norwich University Hospitals NHS Foundations Trust audit department designated this 
as a service improvement exercise and ethical approval was deemed unnecessary. 
 
Statistical Methods 
Basic summary descriptive statistics have been reported comparing patients whose 
ulcers healed within 12 months versus those that did not heal, and also for time to 
healing. The variability in HbA1c was calculated as the standard deviation (SD) of all 
HbA1c observations over the 5 years prior to initial presentation, which had to have 
been recorded at least 30 days from their previous recorded observation. Only patients 
that had had 3 or more Hba1c measurements and had had their measurements 
recorded over a 1 year period had their HbA1c variability calculated. Low mean HbA1c 
was defined as those having a mean HbA1c less than or equal to 58 mmol/mol and high 
mean HbA1c as greater than 58 mmol/mol. The relationship between the mean HbA1c 
and the variability in HbA1c was analysed with variability classified as either low or high 
based on the median. Further analysis of the effect of HbA1c variability was conducted 
by discretising the SD of HbA1c into quartiles. 
 
Basic Chi-square tests were performed to see what factors are associated with ulcer 
healing and logistic regression was performed to adjust for any potential confounding 
factors. The odds ratios for healing and their respective 95% confidence intervals were 
calculated. The secondary outcome variable, time to ulcer healing, was analysed on a 
log transformed scale by a 2 x 2 analysis of variance to see if it was dependent on 
  
Hba1c variability or mean Hba1c. The number of days to heal were transformed back 
onto the natural scale and the geometric means reported with their respective 95% 
confidence intervals. The HbA1c variability quartiles were tested for a difference using 
Tukey’s studentised range test. 
 
Results 
629 new patients were referred to our specialist multidisciplinary foot clinic between July 
2013 and March 2015. 184 patients healed of whom 172 had their number of days to 
healing recorded and a sufficient number of HbA1c concentrations recorded to be 
included in the analysis. A further 117 patients had not healed by the end of the follow 
up period, of whom 116 had a sufficient number of HbA1c concentrations recorded to 
be included in the analysis. Thus 288 are included in the final analysis. The consort 
diagram is shown in Figure 1. The patient characteristics are shown in Table 1. For the 
purposes of this analysis we only included one ulcer per patient. 
 
Our data suggest that there was a statistically significant association between HbA1c 
variability and time to healing.  The overall geometric mean days to heal was 91.1 days 
(SD 80.8 to 102.7). In the low HbA1c variability group the geometric mean days to heal 
was 78.0 days (60.2 to 101.2) vs 126.9 days (102.0 to 158.0) in the high Hb1Ac 
variability group (p=0.032). However the mean HbA1c was also shown to have a more 
significant association with time to healing (p=0.007). Those with low HbA1c (< 
58mmol/mol) and low variability healed faster than those with high HbA1c and high 
variability (73.5 days [59.5 to 90.8] vs 111.0 days [92.0 to134.0], p=0.007).  
  
However, there was no association between the proportion of people who healed and 
HbA1c variability or the mean HbA1c over time. 
 
The rate of ulcer healing was also shown to have a significant association with duration 
of diabetes (p=0.028), ulcer grade (p<0.0001), number of pulses (p<0.0001), Ankle 
Brachial Pressure Index (ABPI) (p=0.021) and a history of foot problems (p=0.045). 
ABPI was only recorded for 93 patients and was still significant.  
 
The ulcer was more likely to heal if the diabetes had been present for more than 8 
years. The odds ratio of healing for DM duration of 8-15 years was 2.72 (95 CI 1.33, 
5.58) compared to having DM for less than 8 years. Additionally, people with medication 
treated type 2 DM had an odds ratio for healing of 2.6 (95% CI: 1.35 4.94) compared to 
people with either Type 1 DM or diet controlled type 2 DM  
 
Discussion  
Our data suggest that glycaemic variability, as measured by the magnitude of standard 
deviation in visit-to-visit changes in HbA1c, has a significant impact on time to wound 
healing in people presenting with diabetes related foot ulcers. However, the association 
between glycaemic variability and the likelihood of wound healing was not statistically 
significant – only the time taken to heal. In addition, that mean HbA1c was a stronger 
predictor of wound healing than glycaemic variability, with high HbA1c concentrations 
being associated with longer healing times. 
 
  
High glycaemic variability is regarded as a reflection of poor health and unstable 
glucose control, which can also be a surrogate marker of patient adherence [17]. Many 
clinicians focus on individual HbA1c values – and indeed, primary care teams in the UK 
have, until recently, been incentivised to achieve low HbA1c values [18]. These targets 
are clearly important and are derived largely from the DCCT and UKPDS [7,8]. 
However, we feel that the added dimension of HbA1c variability could be considered as 
an addition to current practice. Recent work has also suggested an association between 
the combined effect of HbA1c variability and systolic blood pressure in the incidence of 
cardiovascular events amongst patients with diabetes [19], further emphasising the 
importance of regular monitoring modifiable risk factors for cardiovascular disease.  
 
It has previously been suggested that variations in daily glucose concentrations or 
HbA1c may be independently responsible for diabetes-related complications [14,20,21]. 
This can be partly explained by the fact that fluctuations in glucose concentration 
increases the production of reactive oxygen species by the mitochondrial electron-
transport chain resulting in endothelial and β cell dysfunction [22,23]. Other intracellular 
disturbances have also been described [24,25]. Moreover, large glycaemic variability 
over time has been shown to trigger greater levels of oxidative stress when compared to 
sustained hyperglycaemia [26]. Thus glycaemic variability has been proposed as part of 
the unifying mechanism for the development of end organ damage in diabetes [22]. 
These include chronic kidney disease [27,28,29,30], and retinopathy [31]. Furthermore, 
other studies have provided evidence supporting the association of glycaemic variability 
with macrovascular outcomes [32,9]. Previous work has shown that high glycaemic 
  
variability was associated with an increased risk of developing ulcers and gangrene 
[12].  
 
There are various methods proposed for measuring HbA1c variability. A systematic 
review by Eslami et al highlighted the use of thirteen differing methods that may be used 
to assess glycaemic variability; ranging from standard deviation to a glucose variability 
index [33]. We have used SD because it is a simple measurement for population data 
that is applicable to clinical practice. However, opinions differ towards defining 
glycaemic variability and its association with diabetes-related complications. There is 
also little discussion regarding possible influencing factors altering the validity and 
reliability of the methods. Thus, further work is required to establish a definitive method 
for measuring glycaemic variability.  
 
To our knowledge, these are the first data assessing the relationship between HbA1c 
variability and the rate of wound healing in diabetes related foot ulcers. We have 
previously published data to show that patients attending our multidisciplinary foot clinic 
improve their overall glycaemic control whilst they are under our care [34]. The current 
data suggest that this is the most important ‘HbA1c related’ factor when considering 
wound healing and should remain a prime focus of clinicians looking after individuals 
with foot disease, but glycaemic variability clearly also requires more attention.  
 
The reasons for glycaemic variability have not been explored, but would appear to be a 
measurable modifiable risk factor for the development of end organ damage in diabetes. 
  
As with the development of other complication, an unknown factor is patient behaviour. 
It has been shown that people with foot ulcers do not comply with instructions when 
they are asked to wear offloading devices [35], and thus there may be an element of 
intermittent non-concordance with treatment accounting for the variability in HbA1c 
values. In addition, variable adherence with taking medication, or general self-
management may have an impact [11,17]. However, further work needs to be done in 
this emerging area to better understand the causes of variability. 
 
The data to show that the ulcer was more likely to heal if the duration of known diabetes 
was greater than 8 years is somewhat surprising because of the data from the UK 
National Diabetes Foot Audit that showed that a diabetes duration of less than 5 years 
was associated with increased likelihood of healing [36]. Previous authors have shown 
that glycaemic variability was greater when someone had a long duration of diabetes or 
with older age [37]. However, previous work from Sweden also showed that the odds 
ratio of an ulcer healing was marginally higher when the duration of diabetes was 8-15 
years (1.8, [95%CI 1.17-2.77]), compared to a diabetes duration of 0-7 years (1.68, 
[95% CI 1.09-2.28]) [38]. Other data have shown that diabetes duration has no influence 
on ulcer outcomes [39]. 
 
We acknowledge that our data has limitations. We conducted a single centre study 
consisting of a relatively small number of participants, which could have affected the 
validity of the result, particularly given the small numbers of people in each quartile 
range for HbA1c variability. In addition, ours was a convenience sample. Our patient 
  
population was primarily White Caucasians and this may limit the wider generalisability 
of our results. However, most baseline characteristics (diabetes type, gender, age, 
duration) were reflective of typical patient profiles in accordance with the latest UK 
National Diabetes Foot Audit data [36]. Furthermore, due to the nature of our 
retrospective observational study, our study was not designed to investigate whether 
the association was causal or not. By limiting our dataset to those who only had 
sufficient numbers of HbA1c values with which to calculate variability, we have, almost 
by definition, limited ourselves to a) those who turn up to the multidisciplinary foot clinic 
and b) agree to have a blood test. We have not looked at outcomes for those individuals 
who did not fulfil these criteria because that was not the focus of our investigation.  
 
Lastly, our findings were limited by the different number of HbA1c readings available for 
each patient, ranging from 3 to 10 values. Consistent recordings would have allowed for 
a more detailed evaluation towards long-term glycaemic variation. In addition, because 
electronic records for HbA1c were only fully implemented in our institution in 2012 we 
were unable to fully access data from before this date. Furthermore, 10-15% of our case 
load came from other hospitals, and we were unable to access their electronic 
pathology databases to collect their data. This led to the exclusion of patients due to 
insufficient HbA1c values or providing a complete set of readings as per our inclusion 
criteria.  
 
In summary, our data has shown that glycaemic variability, as measured by the 
standard deviation in visit-to-visit changes in HbA1c, has a significant impact on time to 
  
wound healing in people with diabetes related foot ulcers. Wounds take longer to heal in 
people with diabetes with high glycaemic variability, with high HbA1c values also 
influencing the time to wound healing. Whilst in this dataset time to healing was more 
dependent on the mean HbA1c, further work is necessary to confirm the association 
with HbA1c variability. Finally, an analysis of which measure of glycaemic variability is 
the best predictor of outcomes needs to be carried out before it can be routinely 
included in any risk stratification tool.  
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Legend to Figure and Table 
Table 1. Patient characteristics 
 
Figure1. Consort diagram to show patient selection process 
 
 
 
 
  
  
Table 1 (NS – Not significant, SD – Standard deviation) 
 
 
Demographics 
Healed within 1 
year 
Not healed 
within 1 year 
p value 
Mean age at presentation 
(years)  (±SD) 
68.4 (13.8) 
(n=184) 
71.6 (13.4) 
(n=117) 
NS 
Gender (M:F) 
131:52 
(n=183) 
85:32 
(n=117) 
NS 
% Smokers 30.9% (n=93) 19.3% (n=58) NS 
Type of diabetes    
Type 1 13.6 (n=25) 19.7 (n=23)  
Type 2 86.4 (n=159) 80.3 (n=94) NS 
Mean duration of diabetes 
(years) (±SD) 
18.5 (13.2) 
(n=153) 
16.7 (13.7) 
(n=95) 
0.03 
Mean number of HbA1c 
values measured in the 5 
years prior to presentation 
(±SD) 
6.71 (2.73) 
(n=184) 
6.72 (2.62) 
(n=117) 
NS 
Percentage with established 
neuropathy at presentation 
68.5% (n=126) 67.5% (n=79) NS 
  
Percentage with a history of 
revascularisation prior to 
presentation  
7.0% (n=13) 9.5% (n=11) NS 
Mean estimated glomerular 
filtration rate  at presentation 
(mL/min/1.73m2) (±SD) 
60.4 (24.5) 
(n=183) 
60.0 (26.0) 
(n=117) 
NS 
Ankle Brachial Pressure Index    
Missing N (%)  136 (73.9) 75 (64.1)  
<0.5 5 (2.7) 4 (3.4)  
0.5-0.79 7 (3.8) 17 (14.5)  
0.8-1.12 17 (9.2) 14 (12.0)  
>1.12 19 (10.3) 7 (6.0) NS 
Ulcer Grade [Texas] N (%)    
A0 – C0  126 (68.5) 51 (43.6)  
C1 – D3 58 (31.5) 66 (56.4) <0.0001 
Number of Peripheral pulses 
N (%) 
   
None 51 (27.7) 61 (52.1)  
One  39 (21.2) 23 (19.7)  
Two 94 (51.1) 33 (28.2) <0.0001 
 
 
  
Total patients identified (n=629) 
Excluded (n=328) 
 Only 1 follow-up (n=103) 
 No HbA1c data recorded 
(n=7) 
 Insufficient data (n=112) 
 Charcot foot (n=27) 
 Surgical wound (n=6) 
 Dermatological reason 
(n=30) 
 Venous ulcer (n=7) 
 Other (n=36) 
Total patients included in study 
(n=301) 
Patients with healed ulcers within 1 year 
follow-up (n=184) 
Patients with ulcers that were not healed within 
1 year follow-up (n=117) 
Excluded (n=12)  
Did not satisfy HbA1c variability analysis 
criteria (6) 
Missing healing date (6) 
  
Excluded (n=1)  
Did not satisfy HbA1c variability analysis 
criteria  
  
Number included in 
the analysis (n=172) 
Number included in 
the analysis (n=116) 
Total patients that fulfilled inclusion criteria for HbA1c variability 
calculation (n=288) 
 
Figure 1 
  
 
 
  
Highlights 
 
Glycaemic variability – the visit to visit change in HbA1c – has been shown to be 
associated with the risk of developing complications in diabetes.   
 
No work has been done looking at glycaemic variation in the time taken for diabetes 
related foot wounds to heal 
 
Our data suggest that there was a significant association between HbA1c variability 
(as measured by magnitude of standard deviation) and healing time in diabetic foot 
ulcers.  
